| Literature DB >> 27833855 |
Eun-Seok Choi1, Hanna Lee2, Chang-Hun Lee3, Sung-Ho Goh2.
Abstract
Gene fusion, as a prototypical pathognomonic mutation, contributes to genome complexity, and the cis-transcription-induced gene fusions generated by read-through transcription of adjacent genes have been found to be important for tumor development. We screened read-through transcription events from stomach adenocarcinoma RNA-seq data and selected three candidates PHOSPHO2-KLHL23, RPL17-C18orf32, and PRR5-ARHGAP8, to assess their biological role in gastric cancer. The expression of all three read-through fusion transcripts was confirmed in gastric cancer cell lines and paired normal/tumor gastric cancer tissues by real-time quantitative reverse transcription polymerase chain reaction and their expression was found to be significantly higher in the tumor (P < 0.05; n = 75). The correlation between the expression level and clinicopathological information was statistically analyzed. The level of the PHOSPHO2-KLHL23 read-through fusion transcript correlated with the Lauren classification and was significantly associated with the presence of perineural invasion. Overexpression of KLHL23 from PHOSPHO2-KLHL23 read-through transcript led to a significant increase in cell proliferation and resistance to anticancer drug treatment. Silencing of KLHL23 expression decreased cyclin D1 levels. The expression of KLHL23 from prevalent read-through transcripts of PHOSPHO2-KLHL23 in gastric cancer may undermine the efficacy of anticancer drug treatment.Entities:
Keywords: PHOPHO2‐KLHL23; gastric cancer; read‐through transcription
Year: 2016 PMID: 27833855 PMCID: PMC5095152 DOI: 10.1002/2211-5463.12136
Source DB: PubMed Journal: FEBS Open Bio ISSN: 2211-5463 Impact factor: 2.693
Clinicopathological information of gastric cancer patients for mRNA expression‐level assessment between tumor and normal tissues (n = 75)
|
| |
|---|---|
| Number of patients | |
| Total | 75 |
| Male | 53 |
| Female | 22 |
| Age at diagnosis (years) | |
| Range | 21–86 |
| Mean ± SD | 60.7 ± 13.3 |
| Disease stage | |
| Tumor stage | |
| T1a | 0 |
| T1b | 1 |
| T2 | 16 |
| T3 | 29 |
| T4a | 22 |
| T4b | 7 |
| Node stage | |
| N0 | 26 |
| N1 | 11 |
| N2 | 13 |
| N3a | 17 |
| N3b | 8 |
| Metastasis stage | |
| M0 | 63 |
| M1 | 12 |
| Lauren type | |
| Intestinal | 33 |
| Diffuse | 25 |
| Mixed | 7 |
| Indeterminate | 8 |
| Not annotated | 2 |
| Borrmann type | |
| Type I (protruded type) | 1 |
| Type II (ulcerative type) | 21 |
| Type III (ulceroinfiltrative type) | 46 |
| Type IV (diffuse type) | 6 |
| Not determined | 1 |
| Invasion | |
| Perineural | |
| Present | 37 |
| Not identified | 38 |
| Venous | |
| Present | 12 |
| Not identified | 63 |
Figure 1Verification of read‐through fusion transcripts in gastric cancer cell lines. (A) The expression level of three read‐through fusion transcripts was measured with absolute quantitation by qRT‐PCR in gastric cancer cell lines. (B) Genomic alignment of sequenced read‐through fusion transcripts from MKN‐28 gastric cancer cell line. Chromosome location, gene order, read‐through fusion transcript, and fusion protein structure were illustrated. The fusion junction of read‐through transcript was depicted by DNA sequence chromatogram. Gray box indicates proximal gene and black box indicates distal gene.
Figure 2Quantitation of mRNA expression levels of read‐through fusion transcripts in 75 advanced gastric cancer patient tissues. (A) Quantitation of mRNA level of PHOSPHO2, PHOSPHO2‐KLHL23, and KLHL23. (B) Quantitation of mRNA level of RPL17, RPL17‐C18orf32, and C18orf32. (C) Quantitation of mRNA level of distal gene of read‐through fusion transcripts: PRR5, PRR5‐ARHGAP8, and ARHGAP8. The expression of read‐through fusion transcripts was detected at junction region between two genes. Primer pairs anchor on each side of proximal and distal gene, and a junction region‐specific Taqman probe was applied to enhance sequence specificity (*P < 0.05, **P < 0.01, ***P < 0.001; N.S., not significant).
Statistical analyses of read‐through fusion transcript expression with clinicopathological parameters
| Class |
|
|
| |||
|---|---|---|---|---|---|---|
| Mean |
| Mean |
| Mean |
| |
| Lauren classification | ||||||
| Intestinal | 6.03 | 0.040 | 2.21 | 0.208 | 4.27 | 0.054 |
| Diffuse | 2.56 | 1.66 | 1.34 | |||
| Histology | ||||||
| Well diff. | 4.85 | 0.672 | 1.98 | 0.537 | 6.74 | 0.145 |
| Moderate diff. | 3.54 | 1.48 | 2.37 | |||
| Poorly diff. | 5.24 | 1.55 | 0.95 | |||
| Bormann type | ||||||
| Bormann 1 | 3.46 | 0.055 | 1.75 | 0.697 | 3.72 | 0.065 |
| Bormann 2 | 10.39 | 2.52 | 7.45 | |||
| Bormann 3 | 3.95 | 1.67 | 1.60 | |||
| Bormann 4 | 0.84 | 1.04 | 0.64 | |||
| Not identified | 1.52 | 2.27 | 1.60 | |||
| pT stage | ||||||
| T1b | 1.52 | 0.860 | 2.27 | 0.726 | 1.60 | 0.766 |
| T2 | 6.43 | 1.81 | 4.11 | |||
| T3 | 5.00 | 2.25 | 3.05 | |||
| T4a | 3.62 | 1.53 | 1.72 | |||
| T4b | 5.30 | 0.97 | 0.98 | |||
| pN stage | ||||||
| N0 | 6.90 | 0.515 | 2.43 | 0.376 | 4.94 | 0.532 |
| N1 | 3.27 | 1.40 | 2.13 | |||
| N2 | 3.63 | 1.53 | 1.64 | |||
| N3a | 5.43 | 2.04 | 1.76 | |||
| N3b | 2.19 | 0.58 | 1.98 | |||
| Invasion—venous | ||||||
| Present | 6.27 | 0.224 | 1.53 | 0.201 | 1.57 | 0.083 |
| Not identified | 4.70 | 1.89 | 3.00 | |||
| Invasion—perineural | ||||||
| Present | 3.21 | 0.037 | 1.40 | 0.065 | 1.55 | 0.067 |
| Not identified | 6.57 | 2.26 | 4.01 | |||
Figure 3Biological functions of PHOSPHO2‐KLHL23 associated with cell proliferation. (A) PHOSPHO2‐KLHL23 stable transfectant in HEK‐293 cells showed significantly higher wound recover at 12 and 24 h. (B) Knockdown of KLHL23 with the treatment of siRNA induction of cell death protein p53 in AGS cell. On the contrary, it decreased the expression level of cyclin D1. (C) Decrement of p21 protein expression by PHOSPHO2‐KLHL23 overexpression in HEK‐293 cells (inset). Dual‐luciferase assay also showed that PHOSPHO2‐KLHL23 downregulated p21 promoter activity. (D) The PHOSPHO2‐KLHL23 stable transfectant is more resistant to etoposide treatment (< 2.5 μm).